NCT06856226
Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant
StatusRecruiting
PhaseNot specified
Primary completion (estimated)
At risk: Primary completion moved 3 years later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
The 50 most recent of 231 versions: 47 with changes below, 3 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Primary completion pushed from Dec 1, 2027 to Dec 1, 2030
- Study completion pushed from Dec 1, 2028 to Dec 1, 2031
- Minor Start date changed from estimate of Mar 11, 2026 to Mar 4, 2026v227
- Minor Start date: Mar 10, 2026 to Mar 11, 2026v226
- Minor Start date: Mar 9, 2026 to Mar 10, 2026v225
- Minor Start date: Mar 8, 2026 to Mar 9, 2026v224
Show 42 earlier versionsHide 42 earlier versions
- Minor Start date: Mar 5, 2026 to Mar 8, 2026v223
- Minor Start date: Mar 4, 2026 to Mar 5, 2026v222
- Minor Start date: Mar 3, 2026 to Mar 4, 2026v221
- Minor Start date: Mar 2, 2026 to Mar 3, 2026v220
- Minor Start date: Mar 1, 2026 to Mar 2, 2026v219
- Minor Start date: Feb 26, 2026 to Mar 1, 2026v218
- Minor Start date: Feb 25, 2026 to Feb 26, 2026v217
- Minor Start date: Feb 24, 2026 to Feb 25, 2026v216
- Minor Start date: Feb 23, 2026 to Feb 24, 2026v215
- Minor Start date: Feb 22, 2026 to Feb 23, 2026v214
- Minor Start date: Feb 9, 2026 to Feb 22, 2026v213
- Minor Start date: Feb 3, 2026 to Feb 9, 2026v212
- Minor Start date: Feb 2, 2026 to Feb 3, 2026v211
- Minor Start date: Feb 1, 2026 to Feb 2, 2026v210
- Minor Start date: Jan 29, 2026 to Feb 1, 2026v209
- Minor Start date: Jan 28, 2026 to Jan 29, 2026v208
- Minor Start date: Jan 27, 2026 to Jan 28, 2026v207
- Minor Start date: Jan 26, 2026 to Jan 27, 2026v206
- Minor Start date: Jan 22, 2026 to Jan 26, 2026v205
- Minor Start date: Jan 21, 2026 to Jan 22, 2026v204
- Minor Start date: Jan 20, 2026 to Jan 21, 2026v203
- Minor Start date: Jan 19, 2026 to Jan 20, 2026v202
- Minor Start date: Jan 18, 2026 to Jan 19, 2026v201
- Minor Start date: Jan 15, 2026 to Jan 18, 2026v200
- Minor Start date: Jan 14, 2026 to Jan 15, 2026v199
- Minor Start date: Jan 13, 2026 to Jan 14, 2026v198
- Minor Start date: Jan 12, 2026 to Jan 13, 2026v197
- Minor Start date: Jan 11, 2026 to Jan 12, 2026v196
- Minor Start date: Jan 8, 2026 to Jan 11, 2026v195
- Minor Start date: Jan 6, 2026 to Jan 8, 2026v194
- Minor Start date: Jan 5, 2026 to Jan 6, 2026v193
- Minor Start date: Jan 4, 2026 to Jan 5, 2026v192
- Minor Start date: Jan 1, 2026 to Jan 4, 2026v191
- Minor Start date: Dec 30, 2025 to Jan 1, 2026v190
- Minor Start date: Dec 29, 2025 to Dec 30, 2025v189
- Minor Start date: Dec 28, 2025 to Dec 29, 2025v188
- Minor Start date: Dec 25, 2025 to Dec 28, 2025v187
- Minor Start date: Dec 24, 2025 to Dec 25, 2025v186
- Minor Start date: Dec 23, 2025 to Dec 24, 2025v185
- Minor Start date: Dec 22, 2025 to Dec 23, 2025v184
- Minor Start date: Dec 21, 2025 to Dec 22, 2025v183
- Minor Start date: Dec 18, 2025 to Dec 21, 2025v182
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
To determine the most reliable host genomic source for pharmacogenetic testing in participants that have received allogeneic hematopoietic stem cell transplant (HSCT)
Timeframe: Pharmacoscan array will be performed within 1 month pre-BM donation in donors and within 1 month pre-HSCT and 12 months post-HSCT in recipients.
Arms and interventions
Cohort 1
Participants undergoing allogeneic HSCT and donors
Other: Arm 1
Sites
1 site in 1 country
- National Institutes of Health Clinical CenterBethesda, Maryland, United States